🔗 Share this article

This year's Nobel Prize in Physiology or Medicine was awarded for revolutionary findings that clarify how the body's defense network targets harmful pathogens while sparing the healthy tissues.

A trio of esteemed scientists—Japan's Prof. Sakaguchi and US scientists Dr. Brunkow and Fred Ramsdell—received this accolade.

Their work identified unique "security guards" within the immune system that eliminate rogue defense cells capable of harming the body.

These discoveries are now paving the way for new therapies for autoimmune diseases and cancer.

These laureates will divide a prize fund worth 11m Swedish kronor.

Decisive Findings

"Their research has been decisive for comprehending how the body's defenses functions and the reason we don't all suffer from serious self-attack conditions," stated the head of the Nobel Committee.

The team's studies address a core question: How does the defense system defend us from countless invaders while leaving our healthy cells unharmed?

The body's protection system uses white blood cells that search for indicators of infection, including viruses and bacteria it has never encountered.

Such defenders utilize detectors—called receptors—that are generated by chance in a vast number of combinations.

This gives the immune system the capacity to combat a wide array of threats, but the unpredictability of the process inevitably produces immune cells that can target the host.

Protectors of the Immune System

Scientists previously knew that a portion of these problematic white blood cells were destroyed in the immune organ—the site where white blood cells develop.

The latest award recognizes the identification of T-reg cells—described as the immune system's "peacekeepers"—which travel through the system to disarm any defenders that attack the healthy cells.

We know that this mechanism fails in autoimmune diseases such as juvenile diabetes, MS, and RA.

The prize committee added, "These findings have established a new field of research and accelerated the development of innovative treatments, for instance for cancer and immune disorders."

Regarding malignancies, regulatory T-cells prevent the body from fighting the tumor, so studies are focused on lowering their numbers.

In self-attack disorders, trials are exploring boosting regulatory T-cells so the body is not under attack. A comparable method could also be effective in reducing the chances of organ transplant rejection.

Innovative Experiments

Professor Sakaguchi, from a Japanese institution, conducted tests on rodents that had their thymus removed, leading to autoimmune disease.

He demonstrated that introducing immune cells from healthy animals could stop the illness—suggesting there was a mechanism for preventing defenders from attacking the host.

Dr. Brunkow, affiliated with the a research center in a US city, and Fred Ramsdell, currently at a biotech firm in a California city, were studying an genetic immune disorder in rodents and humans that resulted in the identification of a genetic factor critical for how regulatory T-cells function.

"Their pioneering work has revealed how the body's defenses is kept in check by regulatory T cells, stopping it from mistakenly targeting the healthy cells," commented a prominent biological science specialist.

"This research is a striking example of how fundamental physiological research can have far-reaching consequences for public health."